![Fig. 3. Effect of nor-BNI (200 μg intraplantarly or 400 μg subcutaneously) on the antinociceptive action (% maximum possible effect [MPE]) of (A ) FE 200665 (100 μg/paw intraplantarly or 2 mg/rat subcutaneously), (B ) FE 200666 (30 μg/paw intraplantarly or 600 μg/rat subcutaneously), and (C ) U-69,593 (100 μg/paw intraplantarly or 800 μg/rat subcutaneously). *Significant difference from agonist-treated animals, P < 0.05, analysis of variance (Dunnett test). i.pl. = intraplantar; s.c. = subcutaneous.](https://asa2.silverchair-cdn.com/asa2/content_public/journal/anesthesiology/94/6/10.1097_00000542-200106000-00018/2/18ff3.png?Expires=1716462653&Signature=BCx~nj0Fg0X4t-iM6Fa2P5OcsuYi3EoOGkaVogHVu49Yelgwl9hfoItGvGq0PhJiQNkg7kTQEwZ4gqCIP2hv5Oeq9D-PXExMPnX1Ds84~sypH0z2dLKt5M~iPmbF8kS62Mf2KdS1PUEbMW6vZw7SqpBYP1mT~SOfsxhkPEOdSUQX-OfoRklD818A9bvtQqt1VIE6N5xCVybPvq0ZQqngB5w1CLmM8iEhTulfS663VxsQ2hLZejJO19mE2jsnFaXwUdzrD5~IJXmyXePEYN176gCPUhC5DNVJEpJoxDAuMc8YzagbcwDmhqhGnQSnOoXiGBACRhgiKM8T~9j0WSZDAQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Fig. 3. Effect of nor-BNI (200 μg intraplantarly or 400 μg subcutaneously) on the antinociceptive action (% maximum possible effect [MPE]) of (A ) FE 200665 (100 μg/paw intraplantarly or 2 mg/rat subcutaneously), (B ) FE 200666 (30 μg/paw intraplantarly or 600 μg/rat subcutaneously), and (C ) U-69,593 (100 μg/paw intraplantarly or 800 μg/rat subcutaneously). *Significant difference from agonist-treated animals, P < 0.05, analysis of variance (Dunnett test). i.pl. = intraplantar; s.c. = subcutaneous.
